Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | ECE1 | P42892 | 3/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974016 | 0.85 | ECE1 (0.60) | F10ECE1CCR2MAPTNPC1 | |
| SCHEMBL4145769 | 0.84 | ECE1 (0.51) | F10ECE1CCR2NPC1RAB9A | |
| SCHEMBL4150411 | 0.83 | F10 (0.47) | F10ECE1CCR2MAOBABCB1 | |
| SCHEMBL11968337 | 0.83 | F10 (0.47) | F10GRIN1GRIN2BECE1CCR2 | |
| SCHEMBL4146220 | 0.83 | F10 (0.47) | F10GRIN1GRIN2BECE1CCR2 | |
| Hydrochloric Acid SCHEMBL4143378 | 0.83 | F10 (0.47) | F10ECE1CCR2MAOBABCB1 | |
| SCHEMBL4145734 | 0.82 | F10 (0.46) | F10GRIN1GRIN2BECE1CCR2 | |
| SCHEMBL11968329 | 0.81 | ECE1 (0.48) | F10ECE1NPC1RAB9AMAOB | |
| SCHEMBL4143406 | 0.81 | F10 (0.45) | F10GRIN1GRIN2BECE1CCR2 | |
| Hydrochloric Acid SCHEMBL4148851 | 0.80 | ECE1 (0.48) | F10ECE1NPC1RAB9AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481745-B2 | N-(aminoheteroaryl)-1H-indole-2-carboxamide derivatives, preparation thereof and therapeutic use therof | SANOFI (FR) | 2013-07-09 | — | — | US | disclosed |
| US-20120264944-A1 | N-(AMINOHETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEROF | SANOFI (FR) | 2012-10-18 | — | — | US | disclosed |
| EP-2046775-B1 | N-(AMINOHETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2012-08-22 | — | — | EP | disclosed |
| US-8227489-B2 | N-(aminoheteroaryl)-1H-indole-2-carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-07-24 | — | — | US | disclosed |
| US-20090156809-A1 | N-(AMINOHETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264944-A1 | N-(AMINOHETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEROF | IDO2, IDO1, IKZF3 | F10 1188/4885GRIN1 639/4885GRIN2B 1134/4885 |
| US-20090156809-A1 | N-(AMINOHETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | IDO1, IDO2, CNKSR1 | F10 1505/4885GRIN1 632/4885GRIN2B 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.